Gilead Sciences
Also known as: Forty-Seven/Gilead | GILEAD | Gilead, Inc. Investigator Sponsored Research | Gilead Sciences | GILEAD SCIENCES | Gilead Sciences GmbH | Gilead Sciences, Inc. | GILEAD SCIENCES INC | Gilead Sciences, Ltd. | Gilead Sciences, S.L. | Gilead Sciences Study Director | Kite, A Gilead Company | Senior Clinical Research Scientist, Gilead Sciences
Highest phase reached
Phase 4
First clinical trial
Feb 1, 1999First marketed drug
Jun 26, 1996First NDA
Jun 26, 1996Last known activity
May 22, 2026
Timeline
1980s
- Jan 1, 1987
Gilead Sciences— Founded
1990s
- Jul 5, 1999
NeXstar Pharmaceuticals— Acquired
2000s
- Jan 6, 2003
Triangle Pharmaceuticals— Acquired
- Jan 27, 2006
ranolazine— NDA Secondary Org
- Jun 5, 2006
Raylo Chemicals— Acquired
- Jul 19, 2006
Corus Pharma— Acquired
- Oct 3, 2006
Myogen— Acquired
- May 29, 2008
Navitas Pharma— Acquired
- Jan 1, 2009
CV Therapeutics— Acquired
2010s
- Jun 25, 2010
CGI Pharmaceuticals— Acquired
- Dec 10, 2010
Arresto BioSciences— Acquired
- Feb 23, 2011
Calistoga Pharmaceuticals— Acquired
- Jan 1, 2012
Pharmasset— Acquired
- Feb 11, 2013
YM Biosciences— Acquired
- Dec 6, 2013
sofosbuvir— NDA Organization
- Jan 1, 2015
Phenex Pharmaceuticals— Acquired
- May 6, 2015
Epitherapeutics— Acquired
- Apr 4, 2016
Nimbus Apollo— Acquired
- Oct 3, 2017
Kite Pharma, Inc.— Acquired
- Dec 7, 2017
Cell Design Labs— Acquired
- Jul 19, 2018
Gadeta B.V.— Acquired
2020s
- Mar 2, 2020
Forty Seven, Inc.— Acquired
- Jul 21, 2020
Tizona Therapeutics, Inc— Acquired - Sep 14, 2020
Immunomedics— Acquired
- Dec 10, 2020
MYR Pharmaceuticals GmbH— Acquired
- Aug 4, 2022
MiroBio— Acquired
- Dec 22, 2022
lenacapavir— Marketing Organization
- Feb 12, 2024
CymaBay Therapeutics, Inc.— Acquired
Drugs by trial phase (344 distinct, 1052 trials)
Phase 4 (32 own, 14 via acquisition)
Phase 3 (53 own, 44 via acquisition)
Phase 2 (79 own, 43 via acquisition)
Phase 1 (60 own, 18 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Approved for
- Cytomegalovirus Retinitis
- Familial Primary Pulmonary Hypertension
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis C
- Hepatitis C, Chronic
- HIV Infections
- Hypertension, Pulmonary
- Immune System Diseases
- Infections
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Myeloid, Acute
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Muscular Dystrophy, Duchenne
Studied for
- Acquired Immunodeficiency Syndrome
- Acute Coronary Syndrome
- Adenocarcinoma
- Amyloidosis
- Amyotrophic Lateral Sclerosis
- Anemia, Sickle Cell
- Angina Pectoris
- Angina, Stable
- Arrhythmias, Cardiac
- Arteriosclerosis
- Arthritis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Aspergillosis
- Atherosclerosis
- Atrial Fibrillation
- Autoimmune Diseases
- Autoimmune Diseases of the Nervous System
- Blood Coagulation Disorders
- Bone Diseases
- Bone Diseases, Metabolic
- Breast Neoplasms
- Bronchiectasis
- Bronchiolitis
- Bronchiolitis Obliterans
- Burkholderia Infections
- Burkitt Lymphoma
- Candidemia
- Candidiasis
- Candidiasis, Invasive
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Cardiomyopathies
- Cardiomyopathy, Hypertrophic
- Cardiovascular Diseases
- Chest Pain
- Cholangitis
- Cholangitis, Sclerosing
- Cognitive Dysfunction
- Coinfection
- Colitis
- Colitis, Ulcerative
- Colorectal Neoplasms
- Communicable Diseases
- Condylomata Acuminata
- Coronary Artery Disease
- Coronary Disease
- Crohn Disease
- Crush Injuries
- Cryoglobulinemia
- Cystic Fibrosis
- Cystitis
- Cytomegalovirus Retinitis
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Diabetic Neuropathies
- Drug-Related Side Effects and Adverse Reactions
- Dyspnea
- Dyssomnias
- Emergencies
- Esophageal Neoplasms
- Familial Primary Pulmonary Hypertension
- Fatty Liver
- Febrile Neutropenia
- Fibrosis
- Glioblastoma
- Glomerulonephritis, Membranous
- Graft vs Host Disease
- Heart Diseases
- Heart Failure
- Heart Failure, Diastolic
- Hemostatic Disorders
- Hepatitis
- Hepatitis A
- Hepatitis, Alcoholic
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis C
- Hepatitis C, Chronic
- Hepatitis, Chronic
- Hepatitis D
- Hepatitis D, Chronic
- Hepatitis E
- Herpes Simplex
- Herpesviridae Infections
- HIV Infections
- Hodgkin Disease
- Hypertension
- Hypertension, Portal
- Hypertension, Pulmonary
- Hypertrophy
- Idiopathic Pulmonary Fibrosis
- Immunologic Deficiency Syndromes
- Infections
- Inflammatory Bowel Diseases
- Insulin Resistance
- Intestinal Diseases
- Invasive Fungal Infections
Marketed drugs (26)
Subsidiaries (24 direct, 27 total across the full acquisition tree)
- Arresto BioSciences
- Calistoga Pharmaceuticals
- Cell Design Labs
- CGI Pharmaceuticals
- Corus Pharma
- CV Therapeutics
- CymaBay Therapeutics, Inc.
- Epitherapeutics
- Forty Seven, Inc.
- Gadeta B.V.
- Immunomedics
- Kite Pharma, Inc.
- MiroBio
- Myogen
- MYR Pharmaceuticals GmbH
- Navitas Pharma
- NeXstar Pharmaceuticals
- Nimbus Apollo
- Pharmasset
- Phenex Pharmaceuticals
- Raylo Chemicals
- Tizona Therapeutics, Inc
- Triangle Pharmaceuticals
- YM Biosciences
- DataCeutics L2
- Eximias Pharmaceutical L2
- Tmunity Therapeutics L2
Recent trials (50)
- NCT04162756Lead sponsorN/A—
- NCT04162756Study directorN/A—
- NCT04323761Lead sponsorN/A—
- NCT04323761Study directorN/A—
- NCT05627466Lead sponsorN/A—
- NCT05627466Study directorN/A—
- NCT06780579OfficialN/A—
- NCT06780579Lead sponsorN/A—
- NCT05776134Lead sponsorN/A—
- NCT05776134Study directorN/A—
- NCT05776160Lead sponsorN/A—
- NCT05776160Study directorN/A—
- NCT07304154Lead sponsorPhase 1Jan 31, 2026
- NCT07304154OfficialPhase 1Jan 31, 2026
- NCT07178730CollaboratorPhase 3Jan 31, 2026
Details
- Founded
- Foster City, CA, US Jan 1, 1987
- First NDA
- Jun 26, 1996
- Last known activity
- May 22, 2026
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval